Treating the Untreatable: Antisense Oligonucleotides as an Individualized Therapy for Rare Genetic Kidney Diseases.
作者信息
Tekendo-Ngongang Cedrik, Gleeson Joseph G, Mignon Laurence
机构信息
n-Lorem Foundation, San Diego, California.
Rady Children's Institute for Genomic Medicine, San Diego, California.
出版信息
J Am Soc Nephrol. 2024 Dec 1;35(12):1774-1777. doi: 10.1681/ASN.0000000532. Epub 2024 Sep 27.
Abstract
摘要
相似文献
1
Treating the Untreatable: Antisense Oligonucleotides as an Individualized Therapy for Rare Genetic Kidney Diseases.治疗无法治疗的疾病：反义寡核苷酸作为罕见遗传性肾脏疾病的个体化疗法
J Am Soc Nephrol. 2024 Dec 1;35(12):1774-1777. doi: 10.1681/ASN.0000000532. Epub 2024 Sep 27.
2
Milasen: The Emerging Era of Patient-Customized N-of-1 Antisense Oligonucleotides as Therapeutic Agents for Genetic Diseases.
Methods Mol Biol. 2025;2964:85-93. doi: 10.1007/978-1-0716-4730-1_4.
3
Ultrasmall nanoparticles for co-delivery of antisense oligonucleotides targeting miR-21 and miR-210 to treat glioblastoma.用于共递送靶向miR-21和miR-210的反义寡核苷酸以治疗胶质母细胞瘤的超小纳米颗粒。
J Nanobiotechnology. 2025 Jul 2;23(1):482. doi: 10.1186/s12951-025-03529-1.
4
In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy.脊髓性肌萎缩症反义介导外显子包含的体外评估
Methods Mol Biol. 2025;2964:405-420. doi: 10.1007/978-1-0716-4730-1_26.
5
Customized antisense oligonucleotide-based therapy for neurofilament-associated Charcot-Marie-Tooth disease.基于定制反义寡核苷酸的神经丝相关型夏科-马里-图斯病疗法。
Brain. 2024 Dec 3;147(12):4227-4239. doi: 10.1093/brain/awae225.
6
Phosphoramidite Platform for the Automated Synthesis of Morpholino Antisense Oligonucleotides and Their Chimeras.用于自动合成吗啉代反义寡核苷酸及其嵌合体的亚磷酰胺平台。
Curr Protoc. 2025 Jun;5(6):e70162. doi: 10.1002/cpz1.70162.
7
Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.设计用于外显子跳跃和外显子包含的有效剪接转换反义寡核苷酸的技巧。
Methods Mol Biol. 2025;2964:97-108. doi: 10.1007/978-1-0716-4730-1_5.
8
Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series.用于治疗FUS-ALS的反义寡核苷酸药物jacifusen：一项研究者发起的多中心开放标签病例系列研究。
Lancet. 2025 Jun 7;405(10494):2075-2086. doi: 10.1016/S0140-6736(25)00513-6. Epub 2025 May 22.
9
Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation.针对超罕见中枢神经系统疾病的定制反义寡核苷酸：基于经验的个体患者评估最佳实践框架。
Mol Ther Nucleic Acids. 2025 Jul 1;36(3):102615. doi: 10.1016/j.omtn.2025.102615. eCollection 2025 Sep 9.
10
An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.外显子跳跃和剪接调控在肌肉萎缩症及多种遗传疾病中的最新进展与临床应用概述
Methods Mol Biol. 2025;2964:53-83. doi: 10.1007/978-1-0716-4730-1_3.
本文引用的文献
1
Glis2 is an early effector of polycystin signaling and a target for therapy in polycystic kidney disease.Glis2 是多囊肾病中 polycystin 信号的早期效应物，也是治疗的靶点。
Nat Commun. 2024 May 1;15(1):3698. doi: 10.1038/s41467-024-48025-6.
2
Eplontersen: First Approval.依洛硫酸酯酶纳：美国首次批准
Drugs. 2024 Apr;84(4):473-478. doi: 10.1007/s40265-024-02008-5.
3
Personalized antisense oligonucleotides 'for free, for life' - the n-Lorem Foundation.“免费且终身提供”的个性化反义寡核苷酸——n-Lorem基金会。
Nat Med. 2023 Jun;29(6):1302-1303. doi: 10.1038/s41591-023-02335-2.
4
A Potential Therapy Using Antisense Oligonucleotides to Treat Autosomal Recessive Polycystic Kidney Disease.一种使用反义寡核苷酸治疗常染色体隐性多囊肾病的潜在疗法。
J Clin Med. 2023 Feb 10;12(4):1428. doi: 10.3390/jcm12041428.
5
Antisense technology: an overview and prospectus.反义技术：概述与展望。
Nat Rev Drug Discov. 2021 Jun;20(6):427-453. doi: 10.1038/s41573-021-00162-z. Epub 2021 Mar 24.
6
Antisense drug discovery and development technology considered in a pharmacological context.从药理学角度考虑的反义药物发现和开发技术。
Biochem Pharmacol. 2021 Jul;189:114196. doi: 10.1016/j.bcp.2020.114196. Epub 2020 Aug 13.
7
Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5.开发一种针对 X 连锁 Alport 综合征的外显子跳跃治疗方法，该方法针对 COL4A5 中的截断变异。
Nat Commun. 2020 Jun 2;11(1):2777. doi: 10.1038/s41467-020-16605-x.
8
Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease. characterization of the activity and distribution of a 2'-o-methoxyethyl-modified antisense oligonucleotide in models of acute and chronic kidney disease
Nucleic Acid Ther. 2018 Oct;28(5):297-306. doi: 10.1089/nat.2018.0723. Epub 2018 Aug 22.
9
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.依洛瑟那治疗遗传性转甲状腺素蛋白淀粉样变性病患者。
N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.
10
Comparative Renal Toxicopathology of Antisense Oligonucleotides.反义寡核苷酸的比较肾脏毒理病理学
Nucleic Acid Ther. 2016 Aug;26(4):199-209. doi: 10.1089/nat.2015.0598. Epub 2016 Mar 16.
Zotero 插件